Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06715306

Intravenous Versus Oral Treatment of the Main Acute Infections

Patients admitted to the hospital with acute infections are often treated with intravenous (IV) antibiotics. Around 70% of these infections fall into three categories: respiratory tract infections, urinary tract infections, and cellulitis. A Danish study found that 76% of patients admitted with suspected community-acquired pneumonia and treated with antibiotics received them intravenously. Based on an extrapolated estimate from an unpublished local survey, approximately 50,000 patients in Denmark are admitted each year for infections and treated with IV antibiotics. The average hospital stay for these patients is 5.9 days, resulting in a total of 295,000 hospital days annually, accounting for about 7% of total hospital admissions in Denmark. This represents an annual cost of 2.3 billion DKK. While some patients need hospitalization due to their overall health or other serious conditions, others remain hospitalized primarily to receive IV antibiotics.

Expanding the use of oral antibiotics in emergency departments should be pursued only if it can demonstrate comparable efficacy and safety to IV administration. Therefore this study will investigate the efficiency of primarily oral antibiotics in acutely admitted patients with proven or suspected infections. Additionally, the investigators will evaluate the safety of oral regimen for these patients.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sygehus Sønderjylland, Aabenraa, Southern Denmark, Denmark

Loading trial locations.

About this study

Patients admitted to the hospital with infections are often treated with intravenous antibiotics. The rationale for using intravenous antibiotics includes eliminating the risk of reduced absorption, achieving higher serum concentrations, and the fact that many broad-spectrum antibiotics (such as cephalosporins and carbapenems) are not available in oral form. However, intravenous antibiotics also have drawbacks, such as the risk of catheter-related infections, challenges in home-based treatment, and difficulty switching to oral antibiotics unless microbiological results are definitively positive. Prolonged hospital stays associated with intravenous antibiotic treatment lead to economic burdens, increased risk of hospital-acquired infections, and significant functional decline, especially in older patients.

In recent decades, many studies have explored the possibility of fully or partially replacing intravenous antibiotics with oral antibiotics for certain infections.

In this study, the investigators will examine the safety and efficacy of primarily oral antibiotic regimens in patients with confirmed or suspected infections admitted to the emergency department. The study is an open-label, prospective, randomized controlled trial. Participants will be randomly assigned to receive either standard intravenous antibiotic treatment according to Danish guidelines or oral antibiotic treatment based on tailored recommendations developed by microbiologists and infectious disease specialists at participating sites, in accordance with local guidelines.

The study has two primary outcomes: 1) Efficacy-measured as the number of days alive outside the hospital within 30 days after randomization, and 2) Safety-measured by mortality or the need for vasopressors within 30 days after randomization. A total of 4,000 patients will be needed to address both primary outcomes.

Aim: The trial aims to investigate the safety and efficacy of oral antibiotic administration compared to intravenous antibiotic administration in patients referred to the emergency department with suspected or diagnosed bacterial pneumonia, urinary tract infection and cellulitis.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Suspected respiratory tract infection, urinary tract infection, or cellulitis by the attending physician
  • Planned or initiated intravenous antibiotic treatment

Exclusion criteria

  • if received more than two doses of intravenous antibiotics;
  • systolic blood pressure <90 mmHg;
  • nausea and/or vomiting in more than one short-term instance during the last 2 days;
  • suspected significantly reduced gastrointestinal absorption;
  • confirmed plasma-lactate > 2;
  • pregnant or nursing;
  • unable to give informed consent;
  • severe immunodeficiency;
  • urgent vital treatment needed.

Treatment and study plan

Oral treatment

Other

Patients randomized to oral treatment will commence the oral treatment immediately. The oral treatment is based on specially developed treatment suggestions developed by microbiologists and specialists in infectious diseases from the participating regions, and in respect with local treatment guidelines (detailed described in the protocol).

Primary outcomes

  1. Days alive outside hospital (Efficacy)

    Time frame: From randomization date to 30 days

    The number of days the patients are alive outside hospital within 30 days after randomization

  2. Number of patients requiring treatment with vasopressors

    Time frame: From date of randomization to 30 days

    Number of patients that die or number of patients that require treatment with vasopressors within 30 days after randomization

Secondary outcomes

  1. Length of hospital stay

    Time frame: From date of randomization until date of documented hospital discharge or date of death from any cause, whichever came first, assessed up to 6 months

    Duration of hospital length of stay in days

  2. Inhospital mortality

    Time frame: From date of randomization until date of death in hospital from any cause, assessed up to 6 months

    The number of death measured inhospital before discharge

  3. 30-days mortality

    Time frame: up to 30 days from baseline (randomization date)

    The number of death within 30 days

  4. 90-days mortality

    Time frame: Up to 90 days from baseline (randomization date)

    The number of death within 90 days

  5. One-year mortality

    Time frame: Up to one-year from baseline (randomization date)

    The number of death within one-year

  6. Five-year mortality

    Time frame: Up to five-years from baseline (randomization date)

    The number of death within five-years

  7. Discharge within 24 hours

    Time frame: Up to 24 hours after rom baseline (randomization date)

    The number of patients discharged within 24 hours

  8. Readmission

    Time frame: 30 days after discharge date

    The number of patients readmitted to hospital

  9. Intensive care admission

    Time frame: From date of randomization until date of admission to intensive care during hospitalization due to any cause, assessed up to 6 months

    Number of patients admitted to intensive care during current hospital stay

  10. Days on antibiotic treatment within 30 days

    Time frame: Within 30 days from randomization date

    Number of days the patient have been treated with antibiotics

  11. Bacteremia

    Time frame: Day 7 to day 30 from randomization date

    Number of patients diagnosed with bacteremia

Study contacts

Contact information is provided by the study sponsor or research team.

Helene Skjøt-Arkil

CONTACT

[email protected]

+45 79971113

Mariana Bichuette Cartuliares

CONTACT

[email protected]

+45 79971113

Sponsors and collaborators

Lead sponsor

University of Southern Denmark

Other

Registry information

Official study title

Intravenous Versus Oral Treatment of the Main Acute Infections in Emergency Departments

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Dec 4, 2024
Registry last updated
Mar 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.